GSK plc (GSK) Form 6-K — Sep 10, 2026
GSK plc announced that Japan's Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of Shingrix, its recombinant zoster vaccine, for the prevention of shingles. The ready-to-use syringe replaces the prior two-vial format that required manual mixing of a lyophilised antigen and a liquid adjuvant before administration. Shingrix has been approved in Japan since 2018 for adults aged 50 and older and since 2023 for adults 18 and older at increased risk of herpes zoster. Approximately 1.1 million people in Japan develop shingles each year, with risk rising with age and among immunocompromised individuals.
Key figures
- Phn incidence after rash
- up to 30%
- Japan annual shingles cases
- approximately 1.1 million
- Us prefilled syringe launch
- February 2026
- Global lifetime shingles risk
- 1 in 3 adults
- Japan approval adults 50 plus since
- 2018
- Japan approval high risk 18 plus since
- 2023
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.